CGEMY vs GH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CGEMY · CAPGEMINI UNSP ADR EACH REPR 0.2 ORD SHS$28.11 ▼ 3.34%
GH · Guardant Health$150.87 ▼ 1.67%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CGEMY -2.6%
- GH +54.1%
Head to head
| Metric | CGEMY | GH |
|---|---|---|
| Price | $28.11 | $150.87 |
| Change today | ▼ 3.34% | ▼ 1.67% |
| Market cap | $20.36B | $20.41B |
| Return, 3 months | +12.8% | -9.8% |
| Return, year to date | -12.6% | +47.7% |
| Return, 1 year | +1.2% | +56.0% |
| P/E (TTM) | 15.3 | – |
| P/B | 1.8 | -74.0 |
| P/E percentile vs own 5y | – | 8th |
| Dividend yield | 2.80% | – |
| Revenue growth (YoY, latest qtr) | – | +44.3% |
| Net profit growth (YoY) | – | -20.3% |
| Gross margin | – | 65.0% |
| Operating margin | – | -39.7% |
| Net margin | – | -38.3% |
| Return on equity | – | – |
| Analyst target vs. price | – | +35.3% |
| Analyst buy share | – | 100% |
| RSI (14) | 58 | 37 |
| 30-day volatility | 35.9% | 55.1% |
| Max drawdown, 1 year | -43.4% | -33.0% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GH is the largest of the group by market value.
- GH has returned the most over the past year.
- CGEMY has been the calmest stock over the last 30 days.